This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2018 Jan;6(1):5-7.

doi: 10.1016/S2213-8587(17)30368-6. Epub 2017 Nov 9.

Primary aldosteronism and cardiovascular risk, before and after treatment

John W Funder¹

Affiliations

PMID: 29129574
DOI: 10.1016/S2213-8587(17)30368-6

Comment

Primary aldosteronism and cardiovascular risk, before and after treatment

John W Funder. Lancet Diabetes Endocrinol. 2018 Jan.

. 2018 Jan;6(1):5-7.

doi: 10.1016/S2213-8587(17)30368-6. Epub 2017 Nov 9.

Author

John W Funder¹

Affiliation

¹ Hudson Institute of Medical Research and Monash University, Clayton, VIC 3168, Australia. Electronic address: john.funder@hudson.org.au.

PMID: 29129574
DOI: 10.1016/S2213-8587(17)30368-6

No abstract available

PubMed Disclaimer

Comment on

Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysis.
Monticone S, D'Ascenzo F, Moretti C, Williams TA, Veglio F, Gaita F, Mulatero P. Monticone S, et al. Lancet Diabetes Endocrinol. 2018 Jan;6(1):41-50. doi: 10.1016/S2213-8587(17)30319-4. Epub 2017 Nov 9. Lancet Diabetes Endocrinol. 2018. PMID: 29129575

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Other Literature Sources
- scite Smart Citations